Literature DB >> 21623672

Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity.

Eduard A van Hoboken1, Annemieke Y Thijssen, Rob Verhaaren, Patrick P J van der Veek, Frans A Prins, Hein W Verspaget, Ad A M Masclee.   

Abstract

OBJECTIVE: Patients with ulcerative colitis in remission (UCR) frequently report irritable bowel syndrome (IBS)-like symptoms. Recent studies have pointed to the role of mast cells in mediating visceral hypersensitivity in IBS. We hypothesized that visceral hypersensitivity is frequently present in patients with UCR and is related to the quantity and activity of mast cells in the sigmoid mucosa.
MATERIAL AND METHODS: A group of 17 controls and 19 patients with UCR were studied. Rectal compliance and perception were measured by electronic barostat. Sigmoid biopsies were taken to quantify the amount of mast cells, degranulating mast cells and mast cells in close proximity to mucosal nerve endings.
RESULTS: Visceroperception significantly increased in UCR (p < 0.05) versus controls. Rectal perception correlated positively with IBS-like symptoms in UCR (r = 0.969; p < 0.05). The amount of mucosal mast cells (per 100 crypts) was significantly increased in UCR versus controls: 228 ± 20 versus 163 ± 18 (p < 0.05). In the UCR patients a higher percentage of mucosal mast cells was in close proximity to nerve endings (58 ± 4 vs. 38 ± 3% in controls; p < 0.05) or was degranulating (40 ± 7 vs. 16 ± 4% in controls; p < 0.05). There was a significant but weak correlation between quantity of mucosal mast cells and pain perception (r = 0.32; p < 0.05).
CONCLUSION: Rectal hypersensitivity is associated with mucosal presence and activation of mast cells and with IBS-like symptoms in patients with UCR.

Entities:  

Mesh:

Year:  2011        PMID: 21623672     DOI: 10.3109/00365521.2011.579156

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  24 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.

Authors:  Bin Feng; Jun Ho La; Erica S Schwartz; G F Gebhart
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

Review 2.  Antidepressants in inflammatory bowel disease.

Authors:  Antonina Mikocka-Walus; Alexander C Ford; Douglas A Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-18       Impact factor: 46.802

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 4.  AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.

Authors:  Jean-Frederic Colombel; Andrea Shin; Peter R Gibson
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

Review 5.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

Review 6.  The multifaceted mast cell in inflammatory bowel disease.

Authors:  Matthew J Hamilton; Sandra M Frei; Richard L Stevens
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

7.  Pain management in patients with inflammatory bowel disease: insights for the clinician.

Authors:  Arvind Iyengar Srinath; Chelsea Walter; Melissa C Newara; Eva M Szigethy
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

Review 8.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

9.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

10.  The role of colonic mast cells and myenteric plexitis in patients with diverticular disease.

Authors:  Gabrio Bassotti; Vincenzo Villanacci; Riccardo Nascimbeni; Elisabetta Antonelli; Moris Cadei; Stefania Manenti; Luisa Lorenzi; Amin Titi; Bruno Salerni
Journal:  Int J Colorectal Dis       Date:  2012-08-05       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.